Scancell Holdings plc (LON:SCLP – Get Free Report) shares traded down 7.7% on Thursday . The company traded as low as GBX 18.18 and last traded at GBX 18.92. 3,734,724 shares changed hands during trading, an increase of 85% from the average session volume of 2,019,624 shares. The stock had previously closed at GBX 20.50.
Scancell Stock Performance
The stock has a market capitalization of £202.36 million, a price-to-earnings ratio of -35.45 and a beta of 0.57. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The firm has a 50-day moving average of GBX 17.79 and a 200-day moving average of GBX 13.81.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
